EDWARDS LIFESCIENCES CORPORATION (NYSE:EW) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
corporation (Edwards), issued a press release setting forth
Edwards financial results for the first>quarter of 2017. A
copy of the press release is furnished as Exhibit 99.1, and is
incorporated herein by reference.
99.1, shall not be deemed to be filed for purposes of the
Securities Exchange Act of 1934, as amended.
|
(d)
|
Exhibits
|
|
|
99.1
|
Press release, dated April 25, 2017, reporting Edwards
financial results for the first quarter of 2017. |
About EDWARDS LIFESCIENCES CORPORATION (NYSE:EW)
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company manufactures heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. It develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. The Company conducts operations around the world and is managed in various geographical regions, including the United States, Europe, Japan, and Rest of World. All regions sell products that are used to treat advanced cardiovascular disease. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. EDWARDS LIFESCIENCES CORPORATION (NYSE:EW) Recent Trading Information
EDWARDS LIFESCIENCES CORPORATION (NYSE:EW) closed its last trading session up +0.96 at 98.92 with 2,004,360 shares trading hands.
